Published online Sep 26, 2020. doi: 10.4252/wjsc.v12.i9.1013
Peer-review started: June 12, 2020
First decision: July 30, 2020
Revised: August 24, 2020
Accepted: September 1, 2020
Article in press: September 1, 2020
Published online: September 26, 2020
Core Tip: The new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has reached pandemic proportions, causing coronavirus disease (COVID-19), which leads to severe pneumonia. The lungs are the primary organ affected by SARS-CoV-2, with a very slow turnover for renewal. SARS-CoV-2 enters the lungs and induces immune response with cytokine storm and subsequent organ dysfunction. To date, there is no effective antiviral therapy for COVID-19. Cell-based therapy involving mesenchymal stem cells and/or their secretome is considered a supportive therapy for critically ill COVID-19 patients. Mesenchymal stem cells can regenerate severely injured respiratory tract cells through their trophic, anti-inflammatory, and immunomodulatory properties.